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1. Introduction
Chronic  thromboembolic  pulmonary hypertension (CTEPH) is  a  form of  pulmonary hy‐
pertension caused by obstruction and vascular remodeling of the pulmonary arteries after
a pulmonary embolism [1].  Once considered rare, CTEPH is likely under-diagnosed and
its true prevalence is still uncertain [2,3]. CTEPH is a consequence of the persistence and
fibrous organization of clots in the pulmonary arteries after one or more acute pulmonary
emboli. Recent research has provided evidence, suggesting that the old view of CTEPH as
a disease caused solely by obliteration of pulmonary arteries by organized thrombus con‐
stitutes a very superficial  understanding of the consequences of pulmonary thromboem‐
boli [3]. In fact, pulmonary embolism, either as a single episode or as recurrent episodes,
is  probably the trigger followed by progressive pulmonary vascular  remodeling leading
to  elevated  pulmonary  vascular  resistance,  progressing  to  right  ventricular  (RV)  failure
[4].  Thanks to enhanced vascular  and cardiac imaging,  less-invasive diagnostic  work-up
of CTEPH have become widely available. Doppler ultrasound echocardiography and pul‐
monary ventilation/perfusion (V/Q) scintigraphy are two excellent and complementary ex‐
aminations for CTEPH [5]. Computed tomography (CT) and pulmonary angiography are
the two best  tools  to  decide on the operability  of  the endovascular  lesions.  [6].  Equally
important, CTEPH is a type of pulmonary hypertension (PH) that is unique because it is
potentially  curable  by PEA [7,  8].  Indeed,  the prognosis  of  CTEPH was transformed by
this technique [8]. The first surgery for CTEPH was performed in 1958 [9]. The mortality
in the early surgical series was 22% but with advances in surgery and improved and peri‐
operative care, it has decreased to about 4% [10, 11].
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2. Epidemiology of CTEPH
Pulmonary embolism (PE) is a common condition with an annual incidence estimated at 50
per 100,000 persons [12]. This is an acute disease and usually reversible after anticoagulation
and / or after thrombolysis. Patients are frequently deemed to be "cured" after treatment.
However, studies based on V/Q lung or computed tomography pulmonary angiogram (CTPA)
reported the presence of residual perfusion disorders after acute pulmonary embolism [13].
Other echocardiographic studies have also shown that 30% of patients with PAH have residual
or impaired right ventricular wall motion abnormalities and functional impairment after acute
pulmonary embolism [14]. These data suggest that a significant proportion of patients with
acute symptomatic PE develop persistent pulmonary vascular sequelae with serious long-term
consequences [14.15]. Initial estimates of the frequency of CTEPH are of the order of 0.1% to
0.5% of patients surviving an episode of acute pulmonary embolism [16, 17]. More recent data
suggest that 1% to 4% of patients may develop CTEPH after a first episode of pulmonary
embolism [18, 19]. This frequency is even higher after recurrent thromboembolic events [20].
In a series of 866 patients with acute pulmonary embolism, all patients who had not previously
been diagnosed with pulmonary hypertension (PH) and had survived until inclusion in the
study were asked to undergo echocardiography. Patients suspected of having PH by echo‐
cardiogram underwent complete assessment to test chronic thromboembolic pulmonary
hypertension. This procedure includes V/Q scintigraphy and right heart catheterization. The
results showed the incidence of CTEPH to be about 0.5% [21, 22].
In a prospective study, after a first episode of symptomatic pulmonary embolism for pa‐
tients  with unexplained persistent  dyspnea,  echocardiographic  abnormality,  a  V/Q scan,
pulmonary  angiography,  and  right  heart  catheterization,  the  cumulative  incidence  of
symptomatic  CTEPH was  1.0% at  six  months,  3.1% at  one  year  and 3.8% at  two years
[23]. In another study of 320 patients who presented with a symptomatic pulmonary em‐
bolism, V/Q scintigraphy results showed persistent perfusion defects 6 and 12 months af‐
ter  pulmonary  embolism.  The  cumulative  incidence  of  CTEPH  was  0.9%  to  1.3%  [24].
The  true  incidence  of  CTEPH  may  have  been  underestimated  due  to  exclusion  of  pa‐
tients with a history of venous thromboembolism, thrombophilia or other potential caus‐
es  of  pulmonary  hypertension.  In  addition,  a  significant  proportion  of  patients  with
CTEPH have not shown any previous episode of symptomatic pulmonary embolism [25,
26]. The discrepancy between theoretical estimates and the number of patients diagnosed
with CTEPH emphasizes that CTEPH is likely to be underdiagnosed. The time between
an acute pulmonary embolism episode and the development of CTEPH is also a matter
of debate. Most cases of CTEPH are diagnosed during the first two years after the acute
symptomatic  pulmonary embolism [23].  However,  some patients  may experience  symp‐
toms of  CTEPH many years later  [27,  28].  This variability was attributed to progressive
vasculopathy which affected the distal small pulmonary arteries [29].
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3. Risk factors for CTEPH
To better identify patients with pulmonary embolism who are more likely to develop CTEPH,
many studies have assessed the potential risk factors for CTEPH including demographic
factors, the specific details of pulmonary embolism, the presence of co-morbidities and
underlying thrombophilia (table 1) [23, 30]. An increased risk of CTEPH is associated with
splenectomy, cancer, chronic inflammatory diseases (Crohn's disease and ulcerative colitis),
hypothyroidism, an atrioventricular shunt and infected cardiac pacemaker [30, 31]. Compli‐
cations associated with pulmonary embolism such as acute perfusion defects, idiopathic,
recurrent thromboemboli, massive pulmonary emboli, and delayed diagnosis may also
predispose patients to CTEPH. Patients older than 70 years whose systolic pulmonary artery
pressure is above 50 mmHg have a higher risk of persistent pulmonary hypertension one year
after an acute pulmonary embolism [30, 32].
Independent clinical risk factors for CTEPH
• Splenectomy
• Ventriculo-atrial (VA) shunts
• Pacemaker leads
• Indwelling central venous catheters (e.g. Port, Hickman catheter)
• Chronic inflammatory diseases (osteomyelitis, inflammatory bowel
diseases)
• Malignant diseases
• Thyroid hormone replacement therapy
Risk factors associated with CTEPH after symptomatic PE
• Previous pulmonary embolism
• Young age
• Large perfusion defect
• Idiopathic PE at presentation
Plasmatic risk factors associated with CTEPH
• Elevated factor VIII levels "/>250%
• APA/LAC
• Combined coagulation defects
• Fibrinogen mutations
APA, antiphospholipid antibodies; LAC, lupus anticoagulans.
Table 1. Risk factors for CTEPH [23].
Thrombolytics are frequently used to treat acute pulmonary emboli. The rapid and complete
recanalization of the pulmonary arteries may decrease the subsequent development of CTEPH
[33]. 23 of 40 patients who had angiographically proven pulmonary embolism and who had
initially been randomized to an IV infusion of heparin (n = 11) or a thrombolytic agent
(urokinase or streptokinase, n = 12) were restudied after a mean follow-up of 7.4 years to
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measure the right-sided pressures at rest and after supine bicycle ergometry exercise. At rest,
the pulmonary artery (PA) mean pressure and the pulmonary vascular resistance (PVR) were
significantly higher in the heparin group compared with the thrombolytic group (22 vs. 17
mmHg, p<0.05, and 351 vs. 171 dynes s (-1) cm (-5), p<0.02, respectively). During exercise both
parameters rose to a significantly higher level in the heparin group (from rest to exercise, PA:
22-32 mmHg, p<0.01; PVR: 351-437 dynes s (-1) cm 5, p<0.01, respectively), but not in the
thrombolytic group (rest to exercise, PA: 17-19 mm Hg, p = NS; PVR: 171-179 dynes s (-1) cm
(-5), p = NS). Thus, thrombolytic therapy preserves the normal hemodynamic response to
exercise in the long-term and may prevent the development of pulmonary hypertension [34].
CTEPH may be related to a disorder of hemostasis such as elevated levels of factor VIII. The
expression of plasminogen activator inhibitor (PAI-1) of type 1 was found to be higher in
patients monitored for CTEPH [30, 35, 36]. Abnormalities in the structure of fibrinogen and
function were also observed in other series. Traditional risk factors for venous thromboemb‐
olism (VTE) include antithrombin deficiency, protein C deficiency, protein S deficiency, factor
V Leiden, plasminogen deficiency, and anticardiolipin antibodies [26]. However, in 147
consecutive patients with CTEPH, the prevalence of hereditary thrombotic risk factors was not
increased when compared to 99 consecutive patients with IPAH or to 100 control patients.
Recommendation Class of recommendation Level of evidence
The diagnosis of CTEPH is based on the presence of pre-capillary
PH (mean PAP ≥25 mmHg, PCWP ≤15 mmHg, PVR "/>2 Wood
units) in patients with multiple chronic/organized occlusive
thrombi/emboli in the elastic pulmonary arteries (main, lobar,
segmental, subsegmental), persisting after effective
anticoagulation over a minimum period of three months.
I C
In patients with CTEPH, lifelong anticoagulation is indicated I C
Surgical pulmonary endarterectomy (PEA) is the recommended
treatment for patients with CTEPH. I C
Once perfusion scanning and/or CT angiography shows signs
compatible with CTEPH, the patient should be referred to a center
with expertise in surgical pulmonary endarterectomy.
IIa C
The selection of patients for surgery should be
based on the extent and location of the
organized thrombi, on the degree of PH, and
on the presence of co-morbidities.
IIa C
PAH-specific drug therapy may be indicated in
selected CTEPH patients such as patients who
are not candidates for surgery or patients with
residual PH after pulmonary endarterectomy.
IIb C
Table 2. Recommendations of the ESC/ERS guidelines for CTEPH [93].
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Thrombophilia studies have shown that lupus anticoagulant may be found in 10% of CTEPH
patients, and 20% carry antiphospholipid antibodies, lupus anticoagulant, or both. A recent
study has demonstrated that the plasma level of factor VIII, a protein associated with both
primary and recurrent VTE, is elevated in 39% of patients with CTEPH [12]. No abnormalities
of fibrinolysis have been identified. Blood groups type A, B, and AB were found to be
significantly more common in patients with CTEPH compared to patients with PAH (88% vs.
56%). Plasma lipoprotein levels (a) (Lp(a)), a subgroup of the low density lipoprotein with high
atherogenic potency, were significantly higher in patients with CTEPH than in patients with
PAH and control subjects, indicating an overlap of venous and arterial thrombotic risk factors.
Antiphospholipid antibodies (APLA) have been documented in a significant proportion of
patients followed for CTEPH [30, 37, 38]. There is also evidence that underlying genetic
predisposition may be involved in the pathogenesis of CTEPH.
4. Natural history and pathogenesis of CTEPH
The pathophysiological basis of CTEPH is not yet well known. Despite progress in determining
the pathophysiology and treatment of PH, CTEPH pathogenesis is complex and poorly
understood [39]. The mechanisms by which acute pulmonary embolism evolves into chronic
thromboembolic residues incorporated into the pulmonary vessel wall have been difficult to
define [39,40]. The incomplete resolution of pulmonary emboli rather than in situ thrombosis
of pulmonary arteries appears to be the main contributing factor [41]. Pulmonary hypertension
in patients without preexisting cardiopulmonary disease occurs when at least 30% of the
pulmonary vascular bed is obstructed [42]. Development of pulmonary hypertension is not
simply related to a simple mechanical obstruction by chronic thromboembolic material, but
rather the appearance of a secondary vasculopathy developed in regions injured by shear
stresses caused by persistent thromboembolic lesions [43]. Vascular injury and shear stress
eventually lead to the proliferation of endothelial cells and smooth muscle cells of the pulmo‐
nary arterial bed [42, 43, and 44]. These results were reported from pathological observations
in patients examined for CTEPH who displayed an organization of the clot into fibrous tissue,
but also vascular remodeling with disappearance of the intima and infiltration of the media
arterial wall [45, 46, 47, 48, and 49]. This hypothesis was initially suggested by Moser and
Braunwald in 1971 [4]. Indeed, they observed that the pulmonary arteries of small caliber
located in the unobstructed territories had remodeling lesions similar to those described in
idiopathic pulmonary arterial hypertension.
5. Clinical presentation
Generally, the clinical history is not helpful in the diagnosis of CTEPH.. Indeed, up to half of
patients with CTEPH have no documented history of pulmonary embolism [50]. In one series,
63% of patients had no specific history of acute venous thromboembolism [51]. Therefore, the
clinical index of suspicion has been clarified below. The Hispanic clinic has an important place
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in the diagnosis. It identifies clinical events that could be compatible with an unidentified acute
venous thromboembolism [52, 53]. Symptoms of CTEPH are very similar to many other
etiologies of pulmonary arterial hypertension. The majority of patients who displayed CTEPH
were past the age of 60. The symptoms often occurred insidiously and were often attributed
to other cardiac comorbidities, obesity or an underlying lung disease [54]. Dyspnea and fatigue
were the symptoms most frequently encountered. Patients may present with exertional angina,
presyncope, syncope and lower extremity edema. Chest pain may be caused by right ventric‐
ular ischemia. Syncope is an alarming symptom that raises concerns of advanced heart failure
and should prompt urgent examination.
6. Physical examination
Physical signs vary depending on the severity of the pulmonary hypertension and associated
right heart failure. Cardiac auscultation may be notable for accentuated pulmonic valve
closure, tricuspid regurgitant murmur, or possibly bruit over the lung fields caused by
turbulent blood flow through partially occluded pulmonary arteries [55, 56]. At a late stage,
clinical signs of right ventricular failure may be present (jugular venous distension, hepatoju‐
gular reflux, lower limb edema, enlarged liver, and ascites). [56, 57].
7. Diagnostic approach
Patients with CTEPH have a higher mortality rate that may reach up to 10% to 20% among
untreated patients [58, 59]. Thus, the most important step is the early detection of a population
at risk, patients with a CTEPH and the accurate diagnosis of this pathology in order to adopt
the best therapeutic strategy. Patients who experience acute symptomatic pulmonary embo‐
lism, persistent symptoms of dyspnea and chest pain may guide further diagnostic studies.
Moreover, the persistence of pulmonary vascular perfusion defects are also common, 30%
within 12 months after acute pulmonary embolism, and are associated with a higher preva‐
lence of persistent symptoms, worse exercise capacity and pulmonary hypertension [60]. Thus,
clinical and radiologic monitoring may detect patients with pulmonary embolism who have
an increased risk of developing CTEPH.
It is important to acknowledge a history of deep vein thrombosis as an element that can
guide the diagnosis, but it lacks sensitivity. Indeed, many patients with CTEPH have not
had a documented DVT or PE [61,  62].  Patients  monitored for  pulmonary hypertension
of another cause may exhibit symptoms similar to those of CTEPH [63]. V/Q scanning is
an important tool for evaluation of all patients with pulmonary hypertension. It is essen‐
tial because of the fact that CTEPH requires different therapies and may be amenable to
surgical intervention. Thus, the objectives of the diagnostic processes are first to identify
CTEPH, and then to define the stage of the disease and distribution of pulmonary arteri‐
al  occlusion,  with  an  assessment  of  the  severity  of  pulmonary  hypertension  and  other
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concomitant  diseases,  and  finally  determine  eligibility  for  pulmonary  endarterectomy
(PEA) or medical treatment.
After a thorough history and physical exam, patients with suspicious symptoms or signs of
pulmonary hypertension and a history of pulmonary embolism or pulmonary hypertension
of unknown cause should be investigated to confirm or exclude the diagnosis of CTEPH [64].
Imaging is central to making the diagnosis and management of CTEPH, but which test do you
use, and when? The imaging algorithm used at Papworth Hospital for CTEPH diagnosis is
shown in Figure 1. Echocardiography is used in the initial assessment of suspected pulmonary
hypertension. V/Q lung scanning may be used to differentiate chronic thromboembolic
pulmonary hypertension from other causes of pulmonary hypertension.
Figure 1. Diagnostic imaging algorithm for chronic thromboembolic pulmonary hypertension (CTEPH). CT: computed
tomography; MR: magnetic resonance.: pulmonary angiography is usually performed in conjunction with right heart
catheterisation and should be performed at centres experienced with CTEPH and pulmonary endarterectomy [20].
7.1. Echocardiography
Transthoracic echocardiography with Doppler imaging is a sensitive exam for the detection
of pulmonary hypertension and right ventricular dysfunction, but it is not specific for the
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diagnosis of chronic thromboembolic pulmonary hypertension. [65] Common echocardio‐
graphic findings include right ventricular dilatation, hypertrophy, and hypokinesis; right
atrial enlargement; right ventricular pressure overload as suggested by interventricular septal
deviation toward the left ventricle during systole; and tricuspid regurgitation. The tricuspid
regurgitant jet gradient provides an estimate of the pulmonary artery systolic pressure. In rare
cases, transthoracic echocardiography shows proximal pulmonary artery thrombus. However,
echocardiography cannot be used to reliably differentiate among acute, subacute, and chronic
pulmonary embolism. Thus, all patients with pulmonary hypertension should be evaluated
with a V/Q scan [66, 67] in addition to angiography.
7.2. Lung scan ventilation-perfusion
The V/Q lung scan should be performed in patients with PH to look for potentially treatable
CTEPH. The V/Q scan remains the screening method of choice for CTEPH because of its higher
sensitivity relative to CT scans. A normal- or low-probability V/Q scan effectively excludes
CTEPH with a sensitivity of 90–100% and a specificity of 94–100% [68, 69, 76]. A recent study
has shown that lung scintigraphy V/Q had a negative predictive value of 98.5% to exclude
CTEPH, while CT pulmonary angiography had a negative predictive value of 79.7% compared
with pulmonary angiography gold standard. Therefore, a negative pulmonary CT angiogra‐
phy does not formally exclude CTEPH [76].
In PAH the V/Q lung scan may be normal; it may also show small peripheral unmatched
and  nonsegmental  perfusion  defects.  Contrast-enhanced  CT  may  be  used  as  a  comple‐
mentary  investigation  but  does  not  replace  the  ventilation/perfusion  (henceforth  V/Q)
scan or traditional pulmonary angiogram. One caveat is that unmatched perfusion defects
are also seen in pulmonary veno-occlusive disease (PVOD). The V/Q scan in CTEPH typi‐
cally shows multiple segmental or larger perfusion defects in areas of normal ventilation.
Since there is often only partial vascular obstruction in CTEPH, there may be grey zones,
and the lung perfusion scan can underestimate the degree of vascular obstruction. On the
other hand, a normal or low probability V/Q scan virtually excludes the possibility of sur‐
gical intervention of CTEPH [70, 71].
7.3. Computed tomography
The spiral CT has the advantage of being non-invasive, with a spatial resolution close to
pulmonary angiography. In patients with CTEPH, the spiral CT lung may reveal the presence
of an organized thrombus lining the proximal pulmonary vessels and may better visualize
thickening of the pulmonary arterial wall to identify a cleavage plane for endarterectomy.
Conversely, it allows for the identification of atherosclerotic calcification of the arterial wall
lung, which will increase the complexity of PEA. It also evokes rare differential diagnoses such
as fibrous mediastinitis, arteritis, pulmonary emboli tumors or/and sarcomas [72]. The spiral
CT lung is now considered the benchmark in acute pulmonary embolism and can accurately
define the nature and extent of disease in CTEPH, and provide multi-planar reconstruction to
produce a three-dimensional vascular tree [73]. The recent development of this method allows
imaging to differentiate perfusion defects distal to those of proximal infusion [74]. The V/Q
Pulmonary Hypertension150
analysis does not distinguish between acute and chronic embolism. However, several studies
have shown that acute pulmonary embolism disappears within 4 to 6 weeks in 90% of patients
and within 6 months in all patients [75]. Therefore, symptomatic patients in whom perfusion
defects persist despite adequate anticoagulation after 3 to 6 months should be referred to a
specialist center for further evaluation, especially if there is direct or indirect evidence of
pulmonary hypertension in the echocardiography. Sometimes, patients show symptoms at a
later stage after the appearance of the signs of severe right ventricular dysfunction which might
require urgent surgery or semi-urgent surgery, even if they have not yet completed 3 to 6
months of anticoagulation. Right heart catheterization and pulmonary angiography are
generally required for definitive diagnosis of CTEPH. The spiral lung CT is also increasingly
used to assess the extent of chronic thromboembolic disease. However, the spiral CT lung can
sometimes fail to identify the presence of chronic thromboembolic disease.
7.4. Magnetic resonance imaging
This test is also useful for defining the anatomy and extent of obstruction in CTEPH. Currently,
it is not routinely used in patients who can undergo conventional angiography, but in
comparison with spiral CT, it seems to be equivalent for the identification of signs of CTEPH
[77]. Both techniques provide a wealth of additional anatomical information, allowing the
detection of other diagnoses that may be associated with pulmonary hypertension such as
pulmonary vein stenosis and fibrosing mediastinitis.
7.5. Right heart catheterization and pulmonary angiography and angioscopy
7.5.1. Right heart catheterization
Preoperative evaluation of patients with CTEPH requires a battery of complementary exami‐
nations, starting with right heart catheterization and pulmonary angiography [78]. Right heart
catheterization is necessary to confirm the diagnosis and severity of pulmonary hypertension
and provide prognostic information. It allows precise measurement of pulmonary artery
pressure and right atrial pressure, pulmonary artery occlusion pressure, and cardiac output.
In patients with chronic thromboembolic obstruction, PH usually occurs with increased
cardiac output; pulmonary artery pressure will rise in a nearly linear fashion and normal
pulmonary vascular resistance will not occur [79]. In patients with CTEPH and risk factors for
coronary artery disease, left heart catheterization with coronary angiography is performed
before PEA.
7.5.2. Pulmonary angiography
Pulmonary angiography may confirm the diagnosis of chronic pulmonary thromboembolic
disease. The angiographic appearance of CTEPH is distinct from that seen in acute pulmonary
embolism, although the two processes can be seen simultaneously [80]. By defining the
character of the proximal or distal lesions, pulmonary angiography is a determining factor in
the use of PEA. The angiographic abnormalities related to CTEPH include intraluminal filling
defects. A recently developed classification system for the anatomical location of thrombi is
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helpful in the selection of patients for PEA. Type I disease is characterised by a clear central
thrombus; type II consists of the thickening of the intima and fibrous reticulum in a main or
segmental bronchus, without thrombus in a main vessel; type III is limited to segmental or
sub-segmental regions and type IV involves only peripheral vessels and is not an operable
disease.[80, 81]. In addition, pulmonary angiography is not free of significant risk in the context
of severe pulmonary hypertension. Therefore, some security measures should be taken [82,
83]. The biplane acquisition technique should be used whenever possible. The systematic use
of the side view is extremely useful in determining the location and extent of anatomical
proximal embolic obstruction and, therefore, surgical accessibility.
7.5.3. Pulmonary angioscopy
Pulmonary  angioscopy  is  used  as  an  adjunct  to  pulmonary  angiography.  In  the  early
years of endarterectomy, pulmonary angioscopy was used more frequently. More recent‐
ly, it has been replaced by other, less invasive imaging techniques [84]. The technique in‐
volves the introduction of the angioscope through an introducer,  preferably in the right
internal jugular vein, then through the right atrium and right ventricle and the right and
left pulmonary arteries, where it can be guided in each lobe of the arteries. The distal bal‐
loon is  inflated with carbon dioxide,  which obstructs  blood flow transiently  and allows
visualization of the vascular bed [84].
8. Treatment of CTEPH
Several therapies have been used for CTEPH patients since the initial discovery of this clinical
entity [85, 86]. In recent years scientific societies have unanimously endorsed surgical inter‐
vention with PEA as the preferred treatment for CTEPH because of the significant improve‐
ment in survival for the majority of patients and long-term improved outcomes.
PAH specific medications have been investigated in CTEPH, though the number of patients
studied is much smaller than those enrolled in PAH clinical trials. These studies have shown
safety of several therapies, and varying degrees of benefit. Medical therapies are often
considered for use in inoperable patients, or for patients who have residual pulmonary
hypertension after surgery.
The decision to use a specific medication in patients with CTEPH who cannot undergo surgery
or who present with residual PH after surgical intervention should be made after an evaluation
by a referral center. In addition, these patients should remain under close clinical monitoring.
8.1. Surgical approach
8.1.1. Preparation of patients before pulmonary endarterectomy
After diagnostic evaluation, PEA is the treatment of choice for symptomatic patients with
proximal CTEPH. The preoperative assessment of patients scheduled for PEA involves
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evaluating the presence of associated left heart disease with echocardiography to assess LV
size and function as well as coronary angiography to exclude coronary artery disease in the
appropriate patient [87]. Patients are also evaluated for significant concurrent disorders such
as malignancy, using age-appropriate targeted screening, based on careful consideration of
the symptoms presented. Patients are usually maintained on systemic anticoagulation
immediately before surgery, although the actual protocol depends on local experience and
preference of the expert center. Supplemental oxygen and diuretics are often administered to
optimize the patient's oxygen and volume status. Thromboendarerectomy is the treatment of
choice for symptomatic patients with CTEPH when surgically feasible. In some of these
patients, particularly those with severe pulmonary hypertension and right ventricular failure,
medical treatment pre-PEA with parenteral prostanoids (eg epoprostenol) may be initiated as
a bridge to endarterectomy [87, 88, 89].
8.1.2. Pulmonary Endarterectomy (PEA)
Pulmonary endarterectomy is the preferred treatment for patients with CTEPH because of the
potential for cure and complete resolution of PH and its complications. PEA has the potential
to restore near normal cardiopulmonary function. Patient selection for surgery depends on the
extent and location of the organized thrombus in relation to the degree of pulmonary hyper‐
tension. When the thrombus is situated in a proximal location, it represents the ideal condition
for surgery, but if the thrombus is more distal, the intervention becomes more difficult.
8.1.2.1. Surgical strategy
PEA is performed during total circulatory arrest under conditions of profound hypothermia.
This is required to enable visibility in the distal pulmonary arterial branches, which would
otherwise be subject to back-bleeding during the endarterectomy due to the development of
a systemic-to-pulmonary artery circulation at the precapillary level. A relatively recent
technical advance is the introduction of video-assisted pulmonary endarterectomy, which uses
a video camera connected to a rigid angioscope [90, 91]. Video technology is beneficial because
it provides a source of light, allows visualization of the distal pulmonary vascular tree, and
facilitates a close view of the surgery by the assistant surgeons.
8.1.2.2. Surgical procedure
After a median sternotomy, followed by a vertical pericardiotomy, the patient is placed on
cardiopulmonary bypass with hypothermia at 18 to 20 ° C. Before the cardiopulmonary bypass
the patient’s head is wrapped in a blanket with circulating cold water at 4° C. [90, 91]. This
blanket has a thermometer and a device for regulating the water circulation. After the
cardiopulmonary bypass has been started vents are placed in the pulmonary artery and the
right superior pulmonary vein. The right pulmonary artery is dissected between the aorta and
the superior vena cava and is mobilised within the pericardial reflection. During a first period
of circulatory arrest, the plane is circumferentially followed down to the segmental and
sometimes subsegmental branches of each lobe using special suction dissectors, until a
complete endartectomy is achieved. Once the field has been prepared, the endarterectomy
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precedes with the aid of a microscopic aspirator with a rounded tip. The surgical specimen
often resembles the arborization of pulmonary arteries, sometimes containing a mixture of
fresh and old clots. The pulmonary artery pressures are commonly reduced immediately after
surgery. The patient is reperfused for approximately 15 min with cardiopulmonary bypass,
while the arteriotomy is closed with a back-and-forth running suture. An arteriotomy is
performed on the left pulmonary artery and the endarterectomy is repeated in the left lung
within another period of circulatory arrest. The final stage comprises reperfusion during
closure of the left pulmonary artery, de-airing of the cardiac chambers, unclamping of the
aorta, and slow rewarming of the patient to 37°C. [92, 93].
8.1.3. PEA in patients with distal CTEPH
The potential benefits of PEA are uncertain in patients with distal arterial obstruction and
associated CTEPH. Studies have focused specifically on this issue by comparing clinical and
hemodynamic results of surgery in patients with CTEPH and proximal thrombosis or distal
thrombosis [94]. In a study of patients evaluated for CTEPH, 83 patients were considered for
thrombo-endarterectomy [95], 40 patients underwent the procedure of whom 14 had distal
lesions affecting small vessels. In these 14 subjects, PEA was associated with improvement of
the baseline dyspnea index. However, the distal thrombo-endarterectomy was associated with
increased perioperative mortality and severe residual PH post-thrombo-endarterectomy.
Currently, there is no clear consensus on optimal management of distal chronic thromboem‐
bolic disease with associated PH. [94].
8.1.4. Management of patients after surgery
This is a crucial element for the success of the pulmonary PEA. Although pulmonary hemo‐
dynamics improved immediately after surgery in most patients, the postoperative course may
be complicated. Complications are usually not related to any specific aspect of the heart
surgery (pericardial effusion, arrhythmia, atelectasis, wound infection), or specific to the
pulmonary thromboendarterectomy [96]. The postoperative course is marked mainly by the
risk of pulmonary edema-like lesionswhich may appear up to 72 hours after surgery in the
areas where the thromboembolic obstruction was removed [96, 97]. This pulmonary edema is
of varying severity, ranging from a simple acute hypoxemia transition to a fatal hemorrhagic
complication sometimes requiring prolonged mechanical ventilation. Other complications
encountered are right heart failure due to persistent PH, the dehiscence of an arteriotomy
suture during an episode of PAH, nosocomial pneumonia, hemoptysis, which will be easily
treated by embolization, or phrenic nerve paralysis which might prolong mechanical ventila‐
tion.
Reethrombosis in the region of the thromboendarterectomy is a rare but known complication,
especially in unilateral obstruction, which justifies the initiation of anticoagulant therapy as
early as possible after the operation. Patients often continue to improve functionally and
hemodynamicly in the months after the operation.
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8.1.5. Postoperative outcomes
Despite the potential for life-threatening complications, the perioperative mortality of pa‐
tients undergoing lung PEA has improved in recent years. The first results of an interna‐
tional  CTEPH  registry,  which  included  386  consecutive  patients  with  newly  diagnosed
CTEPH  undergoing  surgery  showed  a  significant  and  sustained  decrease  in  PVR  from
736 to  248  dyn s  cm-5,  which  was  accompanied by  substantial  improvements  in  WHO
functional class and exercise capacity at  1 year [97].  Reported rates of residual PH after
PEA (mean PAP> 30 mmHg) were 16.7% and 31%, respectively. More recently, a greatly
reduced surgical mortality rate of 2.2% was reported [98].  Perioperative mortality in pa‐
tients undergoing pulmonary endarterectomy at the University of California at San Diego
was 17% for the first 200 patients who underwent operation from 1970 to 1990 [98]. In a
series from UCSD from 1998 until 2002, 500 patients underwent pulmonary endarterecto‐
my, with a rate of hospital mortality of 4.4% [98]. The preoperative factors that may ad‐
versely  affect  surgical  outcomes  include  age  over  70  years,  the  presence  of  multiple
comorbidities, preoperative pulmonary vascular resistance, severe heart failure with high
right atrial  pressure,  and prolonged duration of pulmonary hypertension before surgery
[99]. In order to detect persistent or recurrent pulmonary hypertension, systematic moni‐
toring surveys are needed. Right heart catheterization is recommended for a period of 6
to 12 months after PEA.
The danger inherent in the initiation of specific medical treatment of pulmonary hypertension
without consultation with a surgeon is that potentially operable patients are not referred to a
center of expertise, and they do not respond to medical treatment or are sent to surgery at an
advanced stage, which is associated with a significantly increased risk. Before starting
treatment, it must be established that the patients are appropriate candidates for the surgical
procedure [100].
8.1.6. Long-term outcomes
Changes in short and long term patient outcomes are generally favorable after PEA. Indeed,
functional and hemodynamic results are very encouraging. Most patients who were New York
Heart Association (NYHA) class III or IV preoperatively became class I or II after surgery and
were able to resume normal activities. A significant reduction and standardization of both
pulmonary artery pressure and resistance may also be affected. In the largest series to date,
the mean pulmonary artery pressure decreased from 46 mm Hg to 28 mm Hg and the mean
pulmonary vascular resistance decreased from 893 to 285 dyne/s-1, [98]. Similar improvements
were observed in right ventricular function by echocardiography, exercise capacity, and
quality of life [101].
8.2. Medical therapy
Pulmonary endarterectomy is the treatment of choice for patients with CTEPH; unfortunately,
it cannot be performed in all CTEPH patients because of the inaccessibility of distal lesions or
the presence of concomitant life-threatening diseases. [102]. In addition, patients with CTEPH
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who have undergone endarterectomy may experience a gradual hemodynamic and sympto‐
matic decline related to a secondary hypertensive arteriopathy in the small precapillary
pulmonary vessels. It has also been questioned what can be done to reduce risks from PEA
surgery to improve outcomes in “high risk” patients with CTEPH with substantial impairment
of pulmonary hemodynamics before surgery. Such patients may benefit from preoperative
reduction of pulmonary vascular resistance by means of medical therapy. Conventional
medical treatments, such as anticoagulation, diuretics, digitalis, and chronic oxygen therapy,
show low efficacy in the treatment of CTEPH as they do not affect underlying disease proc‐
esses. Over the last decade, several novel therapies have been developed for pulmonary arterial
hypertension (PAH), including prostacyclin analogs (epoprostenol, beraprost, iloprost,
treprostinil), endothelin receptor antagonists (bosentan, sitaxsentan, ambrisentan), and
phosphodiesterase-5 inhibitors (sildenafil, tadalafil). Evidence of efficacy in PAH, coupled
with studies showing histopathologic similarities between CTEPH and PAH, provides a
rationale to extend the use of some of these medications to the treatment of CTEPH. However,
direct evidence from clinical trials in CTEPH is limited to date [103, 104].
The BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary
hypertension) study was a double-blind, randomized, placebo-controlled study in CTEPH
including patients with either inoperable CTEPH or persistent/recurrent pulmonary hyper‐
tension after PEA (>6 months after PEA). Independent coprimary end points were change in
PVR as a percentage of baseline and change from baseline in 6-min walk distance after 16 weeks
of treatment [105]. This study demonstrated a positive treatment effect of bosentan on
hemodynamics in this patient population. No improvement was observed in exercise capacity.
Further trials are needed to define the role of medical therapy in patients with CTEPH. In a
retrospective study, the authors analyzed the effects of long-term intravenous epoprostenol
in 27 consecutive functional class III (n = 20) or IV (n = 7) patients with inoperable distal CTEPH.
After three months of epoprostenol, NYHA functional class improved by one class in 11 of 23
surviving patients, 6-minute walk distance increased by 66 m (p 0.0001) and hemodynamics
also improved. At the last evaluation (20 ± 8 months), functional class was improved in 9 of 18
surviving patients with sustained improvement in 6-minute walk distance (+46 m, p = 0.03)
and hemodynamic parameters. Survival at one, two and three years was 73%, 59% and 41%,
respectively [88]. Epoprostenol has also been shown to improve hemodynamics in CTEPH
patients prior to pulmonary thromboendarterectomy. In an open-label uncontrolled study, the
prostacyclin analog treprostinil has been used in patients with severe inoperable CTEPH.
Treprostinil improves exercise capacity, hemodynamics and survival in patients with severe
inoperable CTEPH. We speculate that the effects may be explained by a combined vasodila‐
tory, platelet-antagonistic and potential antiproliferative action of the drug [106].
A double-blind, placebo-controlled, 12-week pilot study investigated the use of sildenafil, 40
mg three times daily, in 19 patients with inoperable CTEPH. Unfortunately, this study was
inadequately powered to test the primary end-point (change in 6-min walk distance). More‐
over, there was no significant difference between the sildenafil and placebo groups (17.5 m
improvement). Nevertheless, there were significant improvements in WHO functional class
(p=0.025) and pulmonary vascular resistance (p=0.044) for the sildenafil-treated [107].
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8.3. Management of patients who are not candidates for endarterectomy
PEA remains the preferred approach for patients with CTEPH. Unfortunately, up to 50% of
patients are not surgical candidates with the most common reasons for exclusion being distal
chronic thromboembolic disease with surgical inaccessibility and significant comorbidities.
Specific medical therapies for PAH in the future can be a real alternative for PEA CTEPH
patients. Although the distinction between PAH and CTEPH is often clear, there are many
similarities between the conditions, including the clinical presentation with progressive PH
and RV failure, and overlapping pathophysiology. PAH and CTEPH may represent extremes
of a continuum of disease based on several data sources such as the observation that micro‐
vascular arteriopathy with plexiform lesions may exist in the vascular bed of both obstructed
and unobstructed patients with CTEPH [109]. The role of several medical therapies in these
specific groups of patients with CTEPH has been explored in many small-uncontrolled studies.
Early indications are that medical therapies may have promise in all these subgroups of
patients with CTEPH, but the precise role of medical treatment in each situation remains
unclear. Studies to date have not demonstrated the same level of efficacy in CTEPH as for
patients with PAH [110]. Other CTEPH patients who might receive PAH medications include
those awaiting lung transplantation. The currently available data do not justify the continua‐
tion of medical treatment in these patients if the waiting time to lung transplantation is long.
8.4. Balloon angioplasty in patients with CTEPH
Some patients with CTEPH, despite proximal (main, lobar or segmental) pulmonary artery
occlusion are not candidates for thromboendarterectomy or decline surgery. In these patients,
balloon angioplasty is a therapeutic option to relieve the obstructed pulmonary artery and
improve the degree of pulmonary hypertension. Uncontrolled case series [111] have demon‐
strated a short-term improvement in pulmonary hemodynamics, WHO functional class, and
exercise capacity.
Although angioplasty may be beneficial, the long term results have not been thoroughly
studied in CTEPH.
8.5. Review of transplantation in patients with CTEPH
Concerned patients with CTEPH in functional class III / IV who are inoperable or have residual
pulmonary hypertension post-PEA are referred for lung transplantation to improve their
clinical outcomes. Although no studies specifically addressing this medical issue have been
identified, patients with CTEPH were included in studies of lung transplantation for pulmo‐
nary hypertension, and in reports from international transplant registries [112]. The average
survival for patients with idiopathic pulmonary hypertension undergoing lung transplanta‐
tion was 5.6 years. The absence of any direct evidence for lung transplantation compared to
medical treatment, especially in patients with CTEPH, was noted. However, the health benefits
of lung transplantation, and a high impact on morbidity and mortality in selected CTEPH
patients was emphasized. The CTEPH patients who are inoperable or experience residual PH
post-PEA and who remain in WHO functional class III or IV, despite optimal medical therapy,
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should be referred for lung transplantation evaluation. Because there can be significant delays
until transplantation, early referral is important.
9. Conclusion
We believe that over the past decade, a paradigm shift has occurred in CTEPH. The disease is
much more common than anticipated and it is imperative that patients with this condition be
adequately diagnosed to have access to surgery and well designed clinical trials. Although
CTEPH is one of the leading causes of severe PH, it remains underdiagnosed. These delays in
diagnosis contribute to the poor prognosis associated with the disease. Diagnosis of CTEPH
requires input from various imaging techniques. Echocardiography, V/Q scintigraphy and
possibly CT angiography are all essential in the initial diagnosis of CTEPH. Pulmonary
angiography remains the gold standard diagnostic technique for assessing operability but
recent advances in CT and MRI angiography show great promise. Furthermore, haemody‐
namic evaluation by right heart catheterisation provides vital prognostic information and an
estimate of the relative risk of PEA surgery. CTEPH should be considered in all patients with
PH as early diagnosis helps to identify those patients suitable for PEA, a potentially curative
treatment. All patients with suspected CTEPH should be referred to an expert centre for a
proper diagnostic evaluation to exclude or confirm the diagnosis and assess operability.
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